Document Detail

Adverse effects of advanced glycation end products on embryonal development.
MedLine Citation:
PMID:  18464885     Owner:  NLM     Status:  MEDLINE    
We studied the effects of advanced glycation end products (AGEs), which are known to accumulate in patients with diabetes, autoimmune diseases, or those who smoke, on embryonal development. Pronuclear (PN) embryos were obtained by flushing the fallopian tubes of rats after superovulation and mating. The cleavage rate and blastocyst yield were evaluated at 24, 72, 96, and 120 h of culture. Glyoxal, an AGE-forming aldehyde, suppressed embryonal development at every stage from PN to blastocyst in a concentration-dependent manner. The cleavage rate of the embryo was also signifi cantly decreased by treatment with glyoxal at concentrations of 1 mM or higher. The blastocyst yield was significantly decreased by treatment with glyoxal at concentrations of 0.5 mM or higher. N-acetyl-L-cysteine (L-NAC) at 1 mM significantly suppressed the glyoxal-induced embryonal toxicity. BSA-AGEs at 5 microg/ml or higher concentration signifi cantly reduced the cleavage rate and blastocyst yield compared to those for BSA-treated embryos. L-NAC at 1 mM significantly suppressed BSAAGE-induced embryonal toxicity. Because AGEs are embryo-toxic, AGE contamination may influence the pregnancy rate of in vitro fertilization and embryo transfer. AGEs, which are increased in women under pathological conditions, may also be involved in their infertility.
Lin Hao; Soichi Noguchi; Yasuhiko Kamada; Aiko Sasaki; Miwa Matsuda; Keiko Shimizu; Yuji Hiramatsu; Mikiya Nakatsuka
Related Documents :
22532885 - Effect of continuous positive airway pressure therapy on glucose control.
3449815 - Effects of hyperglycemia and ketone bodies on the in vitro development of early somite ...
22111945 - Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for dia...
7789645 - Bone loss and bone turnover in diabetes.
18544705 - Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and l...
10857965 - Impaired fasting glucose: how low should it go?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta medica Okayama     Volume:  62     ISSN:  0386-300X     ISO Abbreviation:  Acta Med. Okayama     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-05-09     Completed Date:  2008-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417611     Medline TA:  Acta Med Okayama     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  93-9     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Embryo, Mammalian / cytology,  drug effects*,  physiology
Gestational Age
Glycosylation End Products, Advanced / metabolism,  pharmacology*
Glyoxal / metabolism,  pharmacology*
Rats, Sprague-Dawley
Reg. No./Substance:
0/Glycosylation End Products, Advanced; 107-22-2/Glyoxal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Job strain and smoking cessation among Japanese male employees: a two-year follow-up study.
Next Document:  Effect of pentoxifylline on diaphragmatic contractility in septic rats.